Literature DB >> 22954675

Delineation of molecular pathways that regulate hepatic PCSK9 and LDL receptor expression during fasting in normolipidemic hamsters.

Minhao Wu1, Bin Dong, Aiqin Cao, Hai Li, Jingwen Liu.   

Abstract

BACKGROUND: PCSK9 has emerged as a key regulator of serum LDL-C metabolism by promoting the degradation of hepatic LDL receptor (LDLR). In this study, we investigated the effect of fasting on serum PCSK9, LDL-C, and hepatic LDLR expression in hamsters and further delineated the molecular pathways involved in fasting-induced repression of PCSK9 transcription.
RESULTS: Fasting had insignificant effects on serum total cholesterol and HDL-C levels, but reduced LDL-C, triglyceride and insulin levels. The decrease in serum LDL-C was accompanied by marked reductions of hepatic PCSK9 mRNA and serum PCSK9 protein levels with concomitant increases of hepatic LDLR protein amounts. Fasting produced a profound impact on SREBP1 expression and its transactivating activity, while having modest effects on mRNA expressions of SREBP2 target genes in hamster liver. Although PPARα mRNA levels in hamster liver were elevated by fasting, ligand-induced activation of PPARα with WY14643 compound in hamster primary hepatocytes did not affect PCSK9 mRNA or protein expressions. Further investigation on HNF1α, a critical transactivator of PCSK9, revealed that fasting did not alter its mRNA expression, however, the protein abundance of HNF1α in nuclear extracts of hamster liver was markedly reduced by prolonged fasting.
CONCLUSION: Fasting lowered serum LDL-C in hamsters by increasing hepatic LDLR protein amounts via reductions of serum PCSK9 levels. Importantly, our results suggest that attenuation of SREBP1 transactivating activity owing to decreased insulin levels during fasting is primarily responsible for compromised PCSK9 gene transcription, which was further suppressed after prolonged fasting by a reduction of nuclear HNF1α protein abundance. Published by Elsevier Ireland Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22954675      PMCID: PMC4528917          DOI: 10.1016/j.atherosclerosis.2012.08.012

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  51 in total

1.  Effects of dietary cholesterol and fatty acids on plasma cholesterol level and hepatic lipoprotein metabolism.

Authors:  H Ohtani; K Hayashi; Y Hirata; S Dojo; K Nakashima; E Nishio; H Kurushima; M Saeki; G Kajiyama
Journal:  J Lipid Res       Date:  1990-08       Impact factor: 5.922

2.  Strong induction of PCSK9 gene expression through HNF1alpha and SREBP2: mechanism for the resistance to LDL-cholesterol lowering effect of statins in dyslipidemic hamsters.

Authors:  Bin Dong; Minhao Wu; Hai Li; Fredric B Kraemer; Khosrow Adeli; Nabil G Seidah; Sahng Wook Park; Jingwen Liu
Journal:  J Lipid Res       Date:  2010-01-04       Impact factor: 5.922

3.  Hepatic expression of long-chain acyl-CoA synthetase 3 is upregulated in hyperlipidemic hamsters.

Authors:  Minhao Wu; Haiyan Liu; Wei Chen; Yasuyuki Fujimoto; Jingwen Liu
Journal:  Lipids       Date:  2009-09-15       Impact factor: 1.880

Review 4.  Regulation of the mevalonate pathway.

Authors:  J L Goldstein; M S Brown
Journal:  Nature       Date:  1990-02-01       Impact factor: 49.962

Review 5.  A receptor-mediated pathway for cholesterol homeostasis.

Authors:  M S Brown; J L Goldstein
Journal:  Science       Date:  1986-04-04       Impact factor: 47.728

6.  The association of hepatic apoprotein and lipid metabolism in hamsters and rats.

Authors:  G L Liu; L M Fan; R N Redinger
Journal:  Comp Biochem Physiol A Comp Physiol       Date:  1991

7.  Low-density lipoprotein receptors in rat adipocytes: regulation with fasting.

Authors:  F B Kraemer; C Laane; B Park; C Sztalryd
Journal:  Am J Physiol       Date:  1994-01

8.  The gerbil, hamster, and guinea pig as rodent models for hyperlipidemia.

Authors:  M P Sullivan; J J Cerda; F L Robbins; C W Burgin; R J Beatty
Journal:  Lab Anim Sci       Date:  1993-12

9.  Diminished hepatic response to fasting/refeeding and liver X receptor agonists in mice with selective deficiency of sterol regulatory element-binding protein-1c.

Authors:  Guosheng Liang; Jian Yang; Jay D Horton; Robert E Hammer; Joseph L Goldstein; Michael S Brown
Journal:  J Biol Chem       Date:  2002-01-08       Impact factor: 5.157

10.  Hepatocyte nuclear factor 1alpha plays a critical role in PCSK9 gene transcription and regulation by the natural hypocholesterolemic compound berberine.

Authors:  Hai Li; Bin Dong; Sahng Wook Park; Hyun-Sook Lee; Wei Chen; Jingwen Liu
Journal:  J Biol Chem       Date:  2009-08-17       Impact factor: 5.157

View more
  10 in total

1.  High-fructose feeding promotes accelerated degradation of hepatic LDL receptor and hypercholesterolemia in hamsters via elevated circulating PCSK9 levels.

Authors:  Bin Dong; Amar Bahadur Singh; Salman Azhar; Nabil G Seidah; Jingwen Liu
Journal:  Atherosclerosis       Date:  2015-01-30       Impact factor: 5.162

2.  Sustained and selective suppression of intestinal cholesterol synthesis by Ro 48-8071, an inhibitor of 2,3-oxidosqualene:lanosterol cyclase, in the BALB/c mouse.

Authors:  Jen-Chieh Chuang; Mark A Valasek; Adam M Lopez; Kenneth S Posey; Joyce J Repa; Stephen D Turley
Journal:  Biochem Pharmacol       Date:  2014-01-31       Impact factor: 5.858

3.  Inhibition of PCSK9 transcription by berberine involves down-regulation of hepatic HNF1α protein expression through the ubiquitin-proteasome degradation pathway.

Authors:  Bin Dong; Hai Li; Amar Bahadur Singh; Aiqin Cao; Jingwen Liu
Journal:  J Biol Chem       Date:  2014-12-24       Impact factor: 5.157

4.  Ruxolitinib and Polycation Combination Treatment Overcomes Multiple Mechanisms of Resistance of Pancreatic Cancer Cells to Oncolytic Vesicular Stomatitis Virus.

Authors:  Sébastien A Felt; Gaith N Droby; Valery Z Grdzelishvili
Journal:  J Virol       Date:  2017-07-27       Impact factor: 5.103

5.  Influence of maternal hypercholesterolemia and phytosterol intervention during gestation and lactation on dyslipidemia and hepatic lipid metabolism in offspring of Syrian golden hamsters.

Authors:  Jie Liu; Aadil Iqbal; Amy Raslawsky; Richard W Browne; Mulchand S Patel; Todd C Rideout
Journal:  Mol Nutr Food Res       Date:  2016-06-23       Impact factor: 5.914

6.  FoxO3 transcription factor and Sirt6 deacetylase regulate low density lipoprotein (LDL)-cholesterol homeostasis via control of the proprotein convertase subtilisin/kexin type 9 (Pcsk9) gene expression.

Authors:  Rongya Tao; Xiwen Xiong; Ronald A DePinho; Chu-Xia Deng; X Charlie Dong
Journal:  J Biol Chem       Date:  2013-08-23       Impact factor: 5.157

7.  Plasma PCSK9 concentrations during an oral fat load and after short term high-fat, high-fat high-protein and high-fructose diets.

Authors:  Bertrand Cariou; Cédric Langhi; Maëlle Le Bras; Murielle Bortolotti; Kim-Anne Lê; Fanny Theytaz; Cédric Le May; Béatrice Guyomarc'h-Delasalle; Yassine Zaïr; Roland Kreis; Chris Boesch; Michel Krempf; Luc Tappy; Philippe Costet
Journal:  Nutr Metab (Lond)       Date:  2013-01-08       Impact factor: 4.169

Review 8.  Molecular and cellular function of the proprotein convertase subtilisin/kexin type 9 (PCSK9).

Authors:  Rainer Schulz; Klaus-Dieter Schlüter; Ulrich Laufs
Journal:  Basic Res Cardiol       Date:  2015-01-20       Impact factor: 17.165

9.  Transcriptional control of enterohepatic lipid regulatory targets in response to early cholesterol and phytosterol exposure in apoE-/- mice.

Authors:  Anthony Juritsch; Yi-Ting Tsai; Mulchand S Patel; Todd C Rideout
Journal:  BMC Res Notes       Date:  2017-10-30

Review 10.  PCSK9 signaling pathways and their potential importance in clinical practice.

Authors:  Michał Wiciński; Jarosław Żak; Bartosz Malinowski; Gabriela Popek; Grzegorz Grześk
Journal:  EPMA J       Date:  2017-08-14       Impact factor: 6.543

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.